Streetbeat News

ESALF

Eisai Co Ltd

https://www.eisai.co.jp/

CEO

Haruo Naito

Industry

Pharmaceutical Preparation Manufacturing

Open

32.50

Mkt cap

8.5B

Volume

460

High

32.50

P/E Ratio

32.26

52-wk high

52.97

Low

30.00

Div yield

0.04

52-wk low

30.00

Eisai and Biogen have received a positive opinion from the CHMP for their Alzheimer's treatment, lecanemab, in the EU. This follows a re-examination of a prior negative opinion. The European Commission will decide on the marketing authorization within 67 days.

Portfolio Pulse from

November 14, 2024 | 4:45 pm

Eisai's drug Leqembi has begun its commercial journey with modest market expectations in the US. Despite a setback from the EMA, it has approvals in Japan, US, China, and the UK. Lenvima continues to grow, aiming to meet 2025 targets.

Portfolio Pulse from

November 11, 2024 | 4:00 pm

Eisai Co., Ltd. (ESALF) held its Q2 2025 earnings conference call, discussing its financial performance and operations. Key company participants included CEO Haruo Naito and other executives, with analysts from Citigroup, JPMorgan, Daiwa Securities, and UBS Securities attending.

Portfolio Pulse from

November 09, 2024 | 12:00 pm

Merck and Eisai's Phase 3 LEAP-012 trial shows that the combination of KEYTRUDA and LENVIMA with TACE reduces the risk of disease progression or death by 34% in advanced liver cancer patients compared to TACE alone. These results were presented at the European Society for Medical Oncology Congress 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:36 am

Biogen's Alzheimer's drug, Leqembi, has been approved by the UK's Medicines and Healthcare products Regulatory Agency. However, the National Institute for Health and Care Excellence (NICE) does not recommend it for NHS reimbursement due to cost-effectiveness concerns. Despite showing a small benefit in slowing disease progression, the drug's high costs and limited long-term evidence are barriers.

Portfolio Pulse from Vandana Singh

August 22, 2024 | 5:45 pm

Biogen and Eisai's Alzheimer's drug Leqembi received a negative opinion from the European Medicines Agency's advisory panel due to serious side effects. This decision impacts Biogen's stock, which fell by 6.11%. Eisai plans to seek re-examination of the decision.

Portfolio Pulse from Vandana Singh

July 26, 2024 | 2:21 pm

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a negative opinion on the approval of Eisai and Biogen's Lecanemab for early Alzheimer's treatment. Eisai plans to seek re-examination and work with authorities to make the treatment available in the EU.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 11:24 am

Sen. Bernie Sanders criticized the high cost of healthcare in the U.S., highlighting the financial burden on patients. He specifically mentioned the high prices of drugs from Novo Nordisk, Eisai Co Ltd, Biogen Inc, Johnson & Johnson, Merck, and Bristol-Myers Squibb.

Portfolio Pulse from Benzinga Neuro

July 16, 2024 | 1:36 am

The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease, making it the second anti-beta-amyloid monoclonal antibody approved in recent years. Kisunla shows significant efficacy in reducing amyloid plaques and slowing disease progression. Despite its higher cost compared to Biogen's Leqembi, Kisunla offers the potential for lower long-term costs due to the option of stopping treatment early. Analysts see this approval as a positive development for the Alzheimer's treatment market.

Portfolio Pulse from Vandana Singh

July 03, 2024 | 4:13 pm

Eli Lilly's (LLY) shares are trading higher premarket after an FDA advisory committee gave a favorable verdict on its Alzheimer's treatment, donanemab. The panel's endorsement moves the treatment closer to final FDA approval. The news contrasts Lilly's approach with Biogen's (BIIB) Alzheimer's drug, Leqembi.

Portfolio Pulse from Shivani Kumaresan

June 11, 2024 | 11:51 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.